Logo

    citrome

    Explore "citrome" with insightful episodes like "Dr. Citrome and Dr. Saklad Discuss the Burden of Tardive Dyskinesia" and "Dr. Citrome and Dr. Ospina Discuss Background Information on Tardive Dyskinesia" from podcasts like ""MedEdTalks - Primary Care" and "MedEdTalks - Primary Care"" and more!

    Episodes (2)

    Dr. Citrome and Dr. Saklad Discuss the Burden of Tardive Dyskinesia

    Dr. Citrome and Dr. Saklad Discuss the Burden of Tardive Dyskinesia

    In this podcast, expert clinicians will discuss the burden of tardive dyskinesia (TD) on the patient and health care system. TD is a neurological disorder characterized by persistent involuntary movements that can be debilitating. It is commonly associated with exposure to dopamine receptor antagonists, including both typical and atypical antipsychotics. TD is associated with a high health care burden, but outcomes can be optimized through coordinated care efforts. Recently, the US Food and Drug Administration approved new treatments for patients with TD. Most providers are unfamiliar with these novel therapies and the discrepancies in their use. The other episodes in this series will cover the symptoms, pathology, and causes of TD, as well as available therapies, and multidisciplinary care approaches to consider.

    Transcript: https://tinyurl.com/PrimaryCare3-2

    For CME Credit, complete activity here: https://tinyurl.com/PrimaryCare3-2a

    Dr. Citrome and Dr. Ospina Discuss Background Information on Tardive Dyskinesia

    Dr. Citrome and Dr. Ospina Discuss Background Information on Tardive Dyskinesia

    In this podcast, expert clinicians will discuss the symptoms, pathology, and causes of tardive dyskinesia (TD). TD is a neurological disorder characterized by persistent involuntary movements that can be debilitating. It is commonly associated with exposure to dopamine receptor antagonists, including both typical and atypical antipsychotics. TD is associated with a high health care burden, but outcomes can be optimized through coordinated care efforts. Recently, the US Food and Drug Administration approved new treatments for patients with TD. Most providers are unfamiliar with these novel therapies and the discrepancies in their use. The other episodes in this series will cover the burden of TD, as well as available therapies, and multidisciplinary care approaches to consider.

    Transcript: https://tinyurl.com/PrimaryCare3-1

    For CME Credit, complete activity here: https://tinyurl.com/PrimaryCare3-1a

    Logo

    © 2024 Podcastworld. All rights reserved

    Stay up to date

    For any inquiries, please email us at hello@podcastworld.io